We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




TSH Receptor Antibody Assay Developed for Grave's Disease

By HospiMedica staff writers
Posted on 25 Dec 2007
An automated thyroid-stimulating hormone (TSH) receptor antibody (TRAb) assay is to be developed for the differential diagnosis of Graves' disease. More...
The TRAb test differentiates Graves' disease from toxic nodular goiters.

Graves' disease affects approximately 32 million people worldwide. As one of the most common forms of hyperthyroidism, Graves' is an autoimmune disorder characterized by the presence of stimulating TSH receptor autoantibodies found in approximately 90% of Graves' patients. Stimulating TSH receptor autoantibodies mimic the activity of TSH, leading to an elevated production of thyroid hormone. Left untreated, Graves' disease can lead to miscarriage, birth defects, thyroid eye disease, and even death.

Siemens Medical Solutions Diagnostics (Deerfield, IL, USA) announced that it signed an agreement with KreLo GmbH Medical Diagnostics (Ulm, Germany) for the rights to develop the TRAb assay and expand the thyroid immunoassay menu. Siemens will become the first in-vitro diagnostics distributor of the automated TRAb assay featuring stimulating TRAb KreLo antibodies.

Siemens Medical Solutions Diagnostics provides healthcare professionals a broad range of diagnostic products and services that are used for diagnosing medical conditions, monitoring patient therapy, and providing quality health care. Siemens' range of systems and highly responsive service are designed to improve clinical outcomes, streamline workflow, and enhance the operational efficiency of clinical laboratories worldwide.


Related Links:
Siemens Medical Solutions Diagnostics
KreLo Medical Diagnostics

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Hematology Consumables
Bioblood Devices
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.